Antiproliferatives and Transplantation

Overview

Journal Handb Exp Pharmacol

Specialty Pharmacology

Date 2021 Oct 26

PMID 34697667

Authors

Robert Donovan

Howard Eisen

Omaima Ali

Affiliations

Soon will be listed here.

Abstract

Antiproliferative agents include Mycophenolic acid and Azathioprine (which is less commonly used unless in certain conditions). They were initially identified for use in autoimmune and cancer research due to their role in disruption of cellular replication. They have now become the cornerstone of antirejection maintenance therapy in solid organ transplant. In this chapter we will describe the major times that lead to discovery, mechanisms of action, side effects, use during pregnancy and the major clinical trials.

References

Andreassen A, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E . Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. Am J Transplant. 2016; 16(4):1238-47. DOI: 10.1111/ajt.13588. View

Baran D, Zucker M, Arroyo L, Camacho M, Goldschmidt M, Nicholls S . A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail. 2011; 4(2):129-37. DOI: 10.1161/CIRCHEARTFAILURE.110.958520. View

Byrne R, Yost S, Kaplan B . Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes?. Clin Pharmacol Ther. 2011; 90(2):204-6. DOI: 10.1038/clpt.2011.95. View

Eisen H, Tuzcu E, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler H . Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003; 349(9):847-58. DOI: 10.1056/NEJMoa022171. View

Eisen H, Kobashigawa J, Starling R, Pauly D, Kfoury A, Ross H . Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013; 13(5):1203-16. DOI: 10.1111/ajt.12181. View

ELION G, CALLAHAN S, HITCHINGS G, RUNDLES R . The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man. Cancer Chemother Rep. 1960; 8:47-52. View

Fischer L, Sterneck M, Gahlemann C, Malago M, Rogiers X, Broelsch C . A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc. 2000; 32(7):2125-7. DOI: 10.1016/s0041-1345(00)01599-2. View

Gonwa T, Mendez R, Yang H, Weinstein S, Jensik S, Steinberg S . Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003; 75(8):1213-20. DOI: 10.1097/01.TP.0000062837.99400.60. View

Jeong H, Kaplan B . Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007; 2(1):184-91. DOI: 10.2215/CJN.02860806. View

10.

Ji Y, Gu J, Makhov A, Griffith J, Mitchell B . Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP. J Biol Chem. 2005; 281(1):206-12. DOI: 10.1074/jbc.M507056200. View

11.

Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, ODriscoll G . Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004; 110(17):2694-700. DOI: 10.1161/01.CIR.0000136812.90177.94. View

12.

Kim M, Rostas S, Gabardi S . Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant. 2013; 13(6):1383-9. DOI: 10.1111/ajt.12238. View

13.

Kobashigawa J . Clinical trials in heart transplantation: The evolution of evidence in immunosuppression. J Heart Lung Transplant. 2017; 36(12):1286-1290. DOI: 10.1016/j.healun.2017.10.009. View

14.

Kobashigawa J, Miller L, Russell S, Ewald G, Zucker M, Goldberg L . Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006; 6(6):1377-86. DOI: 10.1111/j.1600-6143.2006.01290.x. View

15.

Maltzman J, Koretzky G . Azathioprine: old drug, new actions. J Clin Invest. 2003; 111(8):1122-4. PMC: 152947. DOI: 10.1172/JCI18384. View

16.

McNeil K, Glanville A, Wahlers T, Knoop C, Speich R, Mamelok R . Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation. 2006; 81(7):998-1003. DOI: 10.1097/01.tp.0000202755.33883.61. View

17.

Merion R, Henry M, Melzer J, Sollinger H, Sutherland D, Taylor R . Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation. 2000; 70(1):105-11. View

18.

Murray J, MERRILL J, Harrison J, Wilson R, DAMMIN G . Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963; 268:1315-23. DOI: 10.1056/NEJM196306132682401. View

19.

Natekar A, Pupco A, Bozzo P, Koren G . Safety of azathioprine use during pregnancy. Can Fam Physician. 2011; 57(12):1401-2. PMC: 3237512. View

20.

Ortega F, Sanchez-Fructuoso A, Cruzado J, Gomez-Alamillo J, Alarcon A, Pallardo L . Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011; 92(4):426-32. DOI: 10.1097/TP.0b013e31822527ca. View